Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP – Get Free Report) saw a significant increase in short interest in the month of February. As of February 28th, there was short interest totalling 452,800 shares, an increase of 112.2% from the February 13th total of 213,400 shares. Based on an average daily volume of 358,400 shares, the short-interest ratio is presently 1.3 days. Currently, 2.7% of the shares of the company are short sold.
Insider Transactions at Acurx Pharmaceuticals
In other Acurx Pharmaceuticals news, CEO David P. Luci bought 49,261 shares of Acurx Pharmaceuticals stock in a transaction dated Monday, January 6th. The stock was bought at an average price of $1.01 per share, with a total value of $49,753.61. Following the completion of the transaction, the chief executive officer now owns 1,097,458 shares in the company, valued at $1,108,432.58. The trade was a 4.70 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 29.60% of the stock is owned by corporate insiders.
Institutional Trading of Acurx Pharmaceuticals
An institutional investor recently raised its position in Acurx Pharmaceuticals stock. Prospect Financial Services LLC increased its position in shares of Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP – Free Report) by 11.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 329,076 shares of the company’s stock after purchasing an additional 34,001 shares during the quarter. Prospect Financial Services LLC owned 1.93% of Acurx Pharmaceuticals worth $268,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 11.53% of the company’s stock.
Acurx Pharmaceuticals Price Performance
Analyst Ratings Changes
Separately, HC Wainwright reissued a “buy” rating and issued a $12.00 price objective on shares of Acurx Pharmaceuticals in a report on Friday, January 10th.
View Our Latest Analysis on Acurx Pharmaceuticals
Acurx Pharmaceuticals Company Profile
Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.
See Also
- Five stocks we like better than Acurx Pharmaceuticals
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- What Are the FAANG Stocks and Are They Good Investments?
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- Earnings Per Share Calculator: How to Calculate EPS
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Acurx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acurx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.